A single 160 mg aspirin tablet a day—costing less than a cup of coffee—cuts the three-year recurrence risk by 55 % in patients whose tumours carry a common mutation, according to the Nordic-led ALASCCA trial. The finding is poised to change post-operative care for up to 40 % of all colorectal-cancer cases in the region.
Business leaders who track healthcare costs may want to add “low-dose aspirin” to their spreadsheets. Data presented this week at the American Society of Clinical Oncology (ASCO) GI Cancers Symposium and simultaneously published in the New England Journal of Medicine show that a three-year course of 160 mg acetylsalicylic acid (ASA) per day almost halves the risk of cancer returning after curative surgery for localised colon and rectal cancer.
The randomised, placebo-controlled ALASCCA trial screened 3,508 patients in 33 Nordic hospitals and ultimately enrolled 626 men and women with stage I–III rectal or stage II–III colon cancer whose tumours harboured mutations in the PI3K signalling pathway—an alteration present in roughly 40 % of colorectal cancers. After median follow-up of 36 months:
- Recurrence rate (aspirin arm): 7.7 %
- Recurrence rate (placebo arm): 15–17 %
- Risk reduction: 55 % across all PI3K-mutated sub-groups
- Serious adverse events: <1 % (one gastrointestinal bleed, one cerebral bleed, one allergic reaction)
Professor Anna Martling, senior surgeon at Karolinska Institutet and first author, told Nordic Business News that the trial is “a textbook example of precision medicine on a shoestring.” She added: “We repurposed a 120-year-old drug that costs <€0.02 per pill and showed it works specifically in the molecular subset that drives a large share of Nordic colorectal-cancer burden.”
Why it matters to executives
Colorectal cancer is the second most costly malignancy in Scandinavia, accounting for >€1.2 billion in direct medical expenditure annually. Roughly 40 % of operated patients relapse; each recurrence adds an estimated €65,000–€100,000 in systemic therapy, sick-leave and productivity losses. A molecularly guided aspirin strategy could therefore save national health systems up to €200 million per year in the Nordics alone, according to a budget-impact model Karolinska shared with Nordic Business News.
Regulatory ripple
The U.S. National Comprehensive Cancer Network already updated its guidelines in April 2025 to recommend PI3K-pathway testing and aspirin use for mutated stage II–III disease. Denmark’s National Board of Health confirmed to Nordic Business News that it will fast-track a technology assessment this autumn, while Sweden’s TLV is reviewing whether to issue a reimbursement code for routine tumour sequencing.
Caveats
- Mutation required: Benefit is confined to patients with PI3K-pathway alterations; testing is mandatory.
- No liver-metastasis data: A separate UCI-led trial recently showed neutral or even harmful effects in metastatic liver-only disease.
- Bleeding risk: Although low, long-term ASA can cause GI or cerebral haemorrhage; investigators recommend proton-pump inhibitor co-medication in patients >70 years or with ulcer history.
Next steps
ALASCCA participants will be followed for five more years to capture overall-survival and late toxicity data. Sub-studies on gender, socioeconomic status and platelet biology are under way, as is a Nordic biobank initiative that will allow start-ups to explore companion diagnostics or liquid-biopsy alternatives.
The bottom line
For a sizeable slice of the region’s colorectal-cancer market, the post-op drug of choice may soon be a generic white pill already stocked in every office first-aid kit. As Martling put it: “Precision medicine does not have to be expensive medicine—sometimes it is simply smart medicine.”
Key Numbers
- 40 % – Share of Nordic colorectal-cancer patients with PI3K mutation eligible for aspirin therapy
- 55 % – Relative reduction in recurrence risk with 160 mg ASA × 3 years
- <1 % – Incidence of grade-3 bleeding in trial cohort
- €0.02 – Approximate cost per 160 mg tablet vs. €3,000–€5,000 per modern adjuvant chemo cycle